In an online edition of the journal Neurology (published online September 12, 2007), Vellinga and colleagues reported results from one site of the pivotal studies suggesting that natalizumab may have a rebound effect on size and development of lesions on MRI scan after withdrawal of natalizumab. This cohort consists of 21 patients and the data was more pronounced in those patients who had initially received placebo and therefore had only short exposure to natalizumab. This data varies from previously reported data that indicates no rebound effect of stopping natalizumab. Future research should be explored to better understand the clinical significance and possible MRI changes following the withdrawal of natalizumab.
Post marketing data regarding the approved therapies for MS continues to be explored and researched to better understand the efficacy and effects of the current medications. This data allows for clinicians and patients to make educated decisions regarding treatments so that optimal responses may occur.
- Font size
- Email This
- Bookmark
- Thank you for your input
- Save
- RSS
- Report Abuse
